CA
NZ
UK
AU
IND
US
Marpai (OTC: MRAI) has renegotiated its AXA agreement, reducing scheduled debt service by $26.4 million and deferring the offering‑proceeds fee until the company secures $5 million from securities offerings. Under the revised schedule, the firm is required to make a $0 payment in 2026, …
Microbot Medical is set to engage with the medical and investment communities at an upcoming industry event, where CEO Harel Gadot will participate in a discussion on neurovascular robotics. The session, part of the Society of Robotic Surgery 2026 program, offers a platform for …
Novo Nordisk has launched a legal offensive against Eli Lilly, accusing its rival of misleading advertising in the fiercely competitive GLP-1 drug market. The lawsuit, filed in an unspecified court, seeks a permanent injunction to halt Lilly’s promotional campaigns and demands corrective advertising to …
The Pentagon’s decision to introduce testosterone replacement therapy (TRT) screening for troops over 30 is sending ripples through the healthcare and defense sectors, with investors weighing the potential benefits against unanswered risks. The move, aimed at male service members without a diagnosed deficiency, has …
Personalis (NASDAQ: PSNL) announced a definitive agreement to become a wholly‑owned subsidiary of Tempus AI through a two‑phase merger structure. Under the plan, a merger subsidiary of Tempus AI will first absorb Personalis, after which the combined entity will merge into a second Tempus …
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) disclosed that its board of directors has been expanded with the addition of Dr. R. Todd Plott, M.D. A board‑certified dermatologist who previously served on an FDA advisory committee.
An analyst’s decision to maintain confidence in Eli Lilly amid a GLP-1 patent lawsuit from a competitor underscores the company’s standing in a highly competitive pharmaceutical sector. The legal challenge, which questions Eli Lilly’s intellectual property related to obesity and diabetes therapies, has raised …
This move is expected to enhance the Company's corporate governance and provide additional protection for its directors and officers. The agreements are subject to the terms and conditions set forth therein, and the Company is required to indemnify and advance expenses to the directors …
60 Degrees Pharmaceuticals is focusing on a commercially available differentiated malaria prevention product while expanding its development efforts for tick-borne diseases. The company’s FDA-approved drug Arakoda serves as the foundation of its commercial strategy as it prepares for future regulatory submissions in new indications. …
Embla Medical outlined a strong second‑quarter performance and delivered an upbeat outlook that resonated across the broader medical‑device environment. The executive team highlighted sustained demand for its core product lines, noting that recent contract wins in the Nordic region support the company’s revenue trajectory. …
Please wait processing your request...